Literature DB >> 22495996

[First experience with the Heidelberg Edge Perimeter® on patients with ocular hypertension and preperimetric glaucoma].

S Hasler1, J Stürmer.   

Abstract

BACKGROUND: The white-on-white computerised static perimetry is not very sensitive to detect a beginning visual field loss. A newer technique to test the central visual field with a flicker defined form technology (FDF) is the Heidelberg Edge Perimeter® (HEP). PATIENTS AND METHODS: A study with 90 eyes from 50 patients (mean age 59 ± 14 years) with ocular hypertension and/or optic nerve suspicious for glaucoma without detectable visual field loss in the Octopus® perimetry (Program dG-2) with the Heidelberg Edge Perimeter® was performed. The "mean defect" (MD), the "pattern standard deviation" and the glaucoma hemifield test (GHT) were calculated and compared with the indices of the Octopus®.
RESULTS: Despite normal visual field findings in the Octopus® perimetry (MD < 2.0 dB) we detected in 48 out of 90 eyes (53 %) pathological visual fields in the HEP examination.
CONCLUSIONS: As a new research method the Heidelberg Edge perimetry® seems to be more sensitive than conventional static perimetry in early detection of visual field alterations in patients between ocular hypertension and incipient glaucoma. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 22495996     DOI: 10.1055/s-0031-1299210

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  [Flicker and conventional perimetry in comparison with structural changes in glaucoma].

Authors:  F Dannheim
Journal:  Ophthalmologe       Date:  2013-02       Impact factor: 1.059

2.  Correlation between early retinal nerve fiber layer loss and visual field loss determined by three different perimetric strategies: white-on-white, frequency-doubling, or flicker-defined form perimetry.

Authors:  Verena Prokosch; Nicole Eter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-30       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.